Donald Munoz.

SEATTLE, BOSTON and TOKYO—Aurion Biotech, Inc., a clinical-stage biotech company that is developing a platform of advanced therapies to treat ocular diseases, announced that Donald Munoz is joining the company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). Munoz is replacing David Rostov as CFO, effective immediately, according to the company. “We are delighted to welcome Don to our executive team,” said Kunst. “Don’s track record of strategic and operational financial leadership, coupled with his extensive experience as a health care investment banker, make him an ideal addition to Aurion.”

According to the announcement, Munoz has more than 30 years of health care experience as a chief financial officer and an investment banker. Prior to joining Aurion, he spent more than nine years as chief financial officer of NuCana plc, a publicly traded biotechnology company developing oncology therapeutics.

 
“I’m thrilled to join Aurion as CFO,” said Munoz. “I believe that Aurion’s lead product candidate, AURN001, has significant potential to treat corneal endothelial disease, which can lead to blindness. I look forward to working with the Aurion team to pursue bringing this cell therapy to patients in need.”